Hauptinhalt

Publikationen

Hier finden Sie Publikationen mit unmittelbarer Beteiligung des KKS Marburg.
Die Publikationen sind nach Jahren sortiert, bitte das entsprechende Jahr auswählen

  • Inhalt ausklappen Inhalt einklappen Publikationen 2020Publikationen 2020

    Stoker, V., P. Krack, L. Tonder, G. Barnett, I. Durand-Zaleski, A. Schnitzler, J.-L. Houeto, L. Timmermann, J. Rau, C. Schade-Brittinger, M. Vidailhet, G. Deuschl and E. S. Group (2020). "Deep Brain Stimulation Impact on Social and Occupational Functioning in Parkinson's Disease with Early Motor Complications." Movement Disorders Clinical Practice 7(6): 672-680.

    Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Röllig C, Wollmer E, Wäsch R, Bornhäuser M, Berg T, Lang F, Ehninger G, Serve H, Zeiser R, Wagner EM, Kroeger N, Wolschke C, Schleuning M, Götze KS, Schmid C, Crysandt M, Eßeling E, Wolf D, Wang Y, Böhm A, Thiede C, Haferlach T, Michel C, Bethge W, Wündisch T, Brandts C, Harnisch S, Wittenberg M, Hoeffkes HG, Rospleszcz S, Burchardt A, Neubauer A, Brugger M, Strauch K, Schade-Brittinger C, Metzelder SK. “Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN).” J Clin Oncol. 2020 Jul 16;JCO1903345. doi: 10.1200/JCO.19.03345. Online ahead of print.

    Pfisterer, J., C. M. Shannon, K. Baumann, J. Rau, P. Harter, F. Joly, J. Sehouli, U. Canzler, B. Schmalfeldt, A. P. Dean, A. Hein, A. G. Zeimet, L. C. Hanker, T. Petit, F. Marmé, A. El-Balat, R. Glasspool, N. de Gregorio, S. Mahner, T. M. Meniawy, T.-W. Park-Simon, M.-A. Mouret-Reynier, C. Costan, W. Meier, A. Reinthaller, J. C. Goh, T. L'Haridon, S. Baron Hay, S. Kommoss, A. du Bois, J.-E. Kurtz et al. (2020). "Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial." The Lancet Oncology 21(5): 699-709.

    Ray-Coquard, I., D. Cibula, M. R. Mirza, A. Reuss, C. Ricci, N. Colombo, H. Koch, F. Goffin, A. Gonzalez-Martin, P. B. Ottevanger, K. Baumann, L. Bjorge, A. Lesoin, A. Burges, P. Rosenberg, M. Gropp-Meier, M. Harrela, P. Harter, J. S. Frenel, T. Minarik, C. Pisano, A. Hasenburg, M. Merger, A. du Bois  on behalf of the AGO Study Group‐led GCIG/ENGOT Intergroup Consortium (2020). "Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer." Int J Cancer 146(2): 439-448.

    Puls HC, Schmidt R, Herpertz S, Zipfel S, Tuschen-Caffier B, Friederich HC, Gerlach F, Mayr A, Lam T, Schade-Brittinger C, de Zwaan M, Hilbert A. Adherence as a predictor of dropout in Internet-based guided self-help for adults with binge-eating disorder and overweight or obesity. Int J Eat Disord. 2019 Dec 31. doi: 10.1002/eat.23220. [Epub ahead of print]

    Barbe MT, Tonder L, Krack P, Debû B, Schüpbach M, Paschen S, Dembek TA, Kühn AA, Fraix V, Brefel-Courbon C, Wojtecki L, Maltête D, Damier P, Sixel-Döring F, Weiss D, Pinsker M, Witjas T, Thobois S, Schade-Brittinger C, Rau J, Houeto JL, Hartmann A, Timmermann L, Schnitzler A, Stoker V, Vidailhet M, Deuschl G; EARLYSTIM study group. Deep Brain Stimulation for Freezing of Gait in Parkinson's Disease With Early Motor Complications. Mov Disord. 2020 Jan;35(1):82-90

    Knudsen, K., P. Krack, L. Tonder, J. L. Houeto, J. Rau, C. Schade-Brittinger, et al. (2019). "Programming parameters of subthalamic deep brain stimulators in Parkinson's disease from a controlled trial." Parkinsonism & Related Disorders 65: 217-223.  https://doi.org/10.1016/j.parkreldis.2019.05.023
     
    Vergote, I., A. du Bois, A. Floquet, J. Rau,  et al. (2019). "Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer." Gynecologic Oncology 155(2): 186-191. https://doi.org/10.1016/j.ygyno.2019.08.024

  • Inhalt ausklappen Inhalt einklappen Publikationen 2019Publikationen 2019

    Mai A, Braun J, Reese JP, Westerhoff B, Trampisch U, Klaassen-Mielke R, Timmesfeld N, Trampisch HJ, Krause D. Nurse-led care versus physician-led care in the management of rheumatoid arthritis and psoriatic arthritis (StaerkeR): study protocol for a multi-center randomized controlled trial. Trials. 2019 Dec 30;20(1):793

    Kircher T, Wöhr M, Nenadic I, Schwarting R, Schratt G, Alferink J, Culmsee C, Garn H, Hahn T, Müller-Myhsok B, Dempfle A, Hahmann M, Jansen A, Pfefferle P, Renz H, Rietschel M, Witt SH, Nöthen M, Krug A, Dannlowski U. Neurobiology of the major psychoses: a translational perspective on brain structure and function-the FOR2107 consortium. Eur Arch Psychiatry Clin Neurosci. 2019 Dec;269(8):949-962

    Vergote I, du Bois A, Floquet A, Rau J, Kim JW, Del Campo JM, Friedlander M, Pignata S, Fujiwara K, Colombo N, Mirza MR, Monk BJ, Tsibulak I, Calvert PM, Herzog TJ, Hanker LC, Meunier J, Lee JY, Bologna A, Carrasco-Alfonso MJ, Harter P. Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. Gynecol Oncol. 2019 Nov;155(2):186-191

    Maurer E, Maschuw K, Reuss A, Zieren HU, Zielke A, Goretzki P, Simon D, Dotzenrath C, Steinmüller T, Jähne J, Kemen M, Coerper S, Leister I, Nies C, Hartel M, Türler A, Holzer K, Agha A, Knoop M, Musholt T, Aminossadati B, Bartsch DK. Total Versus Near-total Thyroidectomy in Graves DiseaseResults of the Randomized Controlled Multicenter TONIG-trial. Ann Surg. 2019 Nov;270(5):755-761.  November 2019

    Bruns I, Schade-Brittinger C, Wissing F, Ruppert T, Trillsch M. Joint recommendationsfor a total services accountas afactor in simplifyingcontracts. Ger Med Sci. 2019 Oct 24;17

    Reuss A, du Bois A, Harter P, Fotopoulou C, Sehouli J, Aletti G, Guyon F, Greggi S, Mosgaard BJ, Reinthaller A, Hilpert F, Schade-Brittinger C, Chi DS, Mahner S. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). Int J Gynecol Cancer. 2019 Oct;29(8):1327-1331

    Woelber L, Eulenburg C, Kosse J, Neuser P, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Jückstock J, Hilpert F, de Gregorio N, Iborra S, Sehouli J, Ignatov A, Hillemanns P, Fürst S, Strauss HG, Mahner S, Prieske K; AGO-CaRE 1 investigators. Predicting the course of disease in recurrent vulvar cancer - A subset analysis of the AGO-CaRE-1 study. Gynecol Oncol. 2019 Sep;154(3):571-576

    Lorusso D, Hilpert F, González Martin A, Rau J, Ottevanger P, Greimel E, Lück HJ, Selle F, Colombo N, Kroep JR, Mirza MR, Berger R, Pardo B, Grischke EM, Berton-Rigaud D, Martinez-Garcia J, Vergote I, Redondo A, Cardona A, Bastière-Truchot L, du Bois A, Kurzeder C; PENELOPE trial investigators. Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer. Int J Gynecol Cancer. 2019 Sep;29(7):1141-1147

    Hauke J, Hahnen E, Schneider S, Reuss A, Richters L, Kommoss S, Heimbach A, Marmé F, Schmidt S, Prieske K, Gevensleben H, Burges A, Borde J, De Gregorio N, Nürnberg P, El-Balat A, Thiele H, Hilpert F, Altmüller J, Meier W, Dietrich D, Kimmig R, Schoemig-Markiefka B, Kast K, Braicu E, Baumann K, Jackisch C, Park-Simon TW, Ernst C, Hanker L, Pfisterer J, Schnelzer A, du Bois A, Schmutzler RK, Harter P. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883). J Med Genet. 2019 Sep;56(9):574-580

    Knudsen K, Krack P, Tonder L, Houeto JL, Rau J, Schade-Brittinger C, Hartmann A, Hälbig TD, Paschen S, Barbe MT, Kühn A, Fraix V, Brefel-Courbon C, Vesper J, Maltête D, Sixel-Döring F, Weiss D, Witjas T, Thobois S, Agid Y, Schnitzler A, Schuepbach WMM, Timmermann L, Damier P, Vidailhet M, Deuschl G; EARLYSTIM study group. Programming parameters of subthalamic deep brain stimulators in Parkinson's disease from a controlled trial. Parkinsonism Relat Disord. 2019 Aug;65:217-223

    Kleinstäuber M., Allwang C., Bailer J., Berking M., Brünahl C., Erkic M., Gitzen H., Gollwitzer M., Gottschalk J.-M., Heider J., Hermann A., Lahmann C., Löwe B., Martin A., Rau J., Schröder A.l, Schwabe J., Schwarz J., Stark R., Weiss F.D., Rief W. Cognitive Behaviour Therapy Complemented with Emotion Regulation Training for Patients with Persistent Physical Symptoms: A Randomised Clinical Trial. Psychother Psychosom. 2019;88(5):287-299

    Villalobos, M., P. Czapiewski, N. Reinmuth, J. R. Fischer, S. Andreas, C. Kortsik, M. Serke, M. Wolf, P. Neuser, A. Reuss, P. A. Schnabel and M. Thomas. Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab. Oncol Lett. 2019 Jun;17(6):4891-4900

    Maurer E, Reuss A, Maschuw K, Aminossadati B, Neubert T, Schade-Brittinger C, Bartsch DK. Oberflächliche Wundinfekte nach intrakutaner Hautnaht versus Klammernaht Eine prospektive randomisierte monozentrische Studie in der elektiven gastrointestinalen Chirurgie. Dtsch Arztebl Int 2019; 116(21): 365-71

    Deuschl G, Follett KA, Luo P, Rau J, Weaver FM, Paschen S, Steigerwald F, Tonder L, Stoker V, Reda DJ. Comparing two randomized deep brain stimulation trials for Parkinson’s disease. J Neurosurg. 2019 Apr 5:1-9

    Hopfner F, Müller SH, Steppat D, Miller J, Schmidt N, Wandinger KP, Leypoldt F, Berg D, Franke A, Lieb W, Tittmann L, Balzer-Geldsetzer M, Baudrexel S, Dodel R, Hilker-Roggendorf R, Kalbe E, Kassubek J, Klockgether T, Liepelt-Scarfone I, Mollenhauer B, Neuser P, Reetz K, Riedel O, Schulte C, Schulz JB, Spottke A, Storch A, Trenkwalder C, Wittchen HU, Witt K, Wüllner U, Deuschl G, Kuhlenbäumer G. No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors. Transl Neurodegener. 2019 Apr 3;8:11

    Schuepbach WMM, Tonder L, Schnitzler A, Krack P, Rau J, Hartmann A, Hälbig TD, Pineau F, Falk A, Paschen L, Paschen S, Volkmann J, Dafsari HS, Barbe MT, Fink GR, Kühn A, Kupsch A, Schneider GH, Seigneuret E, Fraix V, Kistner A, Chaynes PP, Ory-Magne F, Brefel-Courbon C, Vesper J, Wojtecki L, Derrey S, Maltête D, Damier P, Derkinderen P, Sixel-Döring F, Trenkwalder C, Gharabaghi A, Wächter T, Weiss D, Pinsker MO, Regis JM, Witjas T, Thobois S, Mertens P, Knudsen K, Schade-Brittinger C, Houeto JL, Agid Y, Vidailhet M, Timmermann L, Deuschl G; EARLYSTIM study group. Quality of life predicts outcome of deep brain stimulation in early Parkinson disease. Neurology. 2019 Mar 5;92(10):e1109-e1120

    Bagnoli M, Shi TY, Gourley C, Speiser P, Reuss A, Nijman HW, Creutzberg CL, Scholl S, Negrouk A, Brady MF, Hasegawa K, Oda K, McNeish IA, Kohn EC, Oza AM, MacKay H, Millan D, Bennett K, Scott C, Mezzanzanica D. Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions. Cells. 2019 Feb 26;8(3)

    P. Harter, J. Sehouli, D. Lorusso, A. Reuss, I. Vergote, C. Marth, J.-W. Kim, F. Raspagliesi, B. Lampe, G. Aletti, W. Meier, D. Cibula, A. Mustea, S. Mahner, I.B. Runnebaum, B. Schmalfeldt, A. Burges, R. Kimmig, G. Scambia, S. Greggi, F. Hilpert, A. Hasenburg, P. Hillemanns, G. Giorda, I. von Leffern, C. Schade‑Brittinger, U. Wagner, and A. du Bois. A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms. N Engl J Med 2019;380:822-32

    Hessmann P, Dodel R, Baum E, Müller MJ, Paschke G, Kis B, Zeidler J, Klora M, Reese JP, Balzer-Geldsetzer M. Prescription of Benzodiazepines and Related Drugs in Patients with Mild Cognitive Deficits and Alzheimer's Disease. Pharmacopsychiatry. 2019 Feb;52(2):84-91

    Wojtala J, Heber IA, Neuser P, Heller J, Kalbe E, Rehberg SP, Storch A, Linse K, Schneider C, Gräber S, Berg D, Dams J, Balzer-Geldsetzer M, Hilker-Roggendorf R, Oberschmidt C, Baudrexel S, Witt K, Schmidt N, Deuschl G, Mollenhauer B, Trenkwalder C, Liepelt-Scarfone I, Spottke A, Roeske S, Wüllner U, Wittchen HU, Riedel O, Dodel R, Schulz JB, Reetz K. Cognitive decline in Parkinson's disease: the impact of the motor phenotype on cognition. J Neurol Neurosurg Psychiatry. 2019 Feb;90(2):171-179

    Heitz F, Harter P, Åvall-Lundqvist E, Reuss A, Pautier P, Cormio G, Colombo N, Reinthaller A, Vergote I, Poveda A, Ottevanger PB, Hanker LC, Leminen A, Alexandre J, Canzler U, Sehouli J, Herrstedt J, Fiane B, Merger M, du Bois A. Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. Gynecol Oncol. 2019 Feb;152(2):235-242

  • Inhalt ausklappen Inhalt einklappen Publikationen 2018Publikationen 2018

    Willems LM, Richter S, Watermann N, Bauer S, Klein KM, Reese JP, Schöffski O, Hamer HM, Knake S, Rosenow F, Strzelczyk A. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany from 2003 to 2013 - A ten-year overview. Epilepsy Behav. 2018 Jun;83:28-35. Med Oncol. 2018 Jun 15;35(7):10

    Villalobos M, Czapiewski P, Reinmuth N, Fischer JR, Andreas S, Kortsik C, Serke M, Wolf M, Neuser PReuss A, Schnabel PA,·Thomas M. ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer. Med Oncol. 2018 Jun 15;35(7):106.

    Greulich T, Hohlfeld JM, Neuser P, Lueer K, Klemmer A, Schade-Brittinger C, Harnisch S, Garn H, Renz H, Homburg U, Renz J, Kirsten A, Pedersen F, Müller M, Vogelmeier CF, Watz H. A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial. Respir Res. 2018 Apr 4;19(1):55

    Eugénie Lhommée, Lars Wojtecki, Virginie Czernecki, Karsten Witt, Franziska Maier, Lisa Tonder, Lars Timmermann, Thomas D Hälbig , Fanny Pineau, Franck Durif, Tatiana Witjas, Marcus Pinsker, Maximilian Mehdorn, Friederike Sixel-Döring, Andreas Kupsch, Rejko Krüger, Saskia Elben, Stephan Chabardès, Stéphane Thobois, Christine Brefel-Courbon, Fabienne Ory-Magne, Jean-Marie Regis, David Maltête,Anne Sauvaget, Jörn Rau, Alfons Schnitzler, Michael Schüpbach, Carmen Schade-Brittinger, Gunther Deuschl, Jean-Luc Houeto, Paul Krack, in collaboration with the EARLYSTIM study group. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson’s disease with early motor complications (EARLYSTIM trial):secondary analysis of an open-label randomised trial. Lancet Neurol 2018 Mar; 17(3):223–231

    Hessmann P, Dodel R, Baum E, Müller MJ, Paschke G, Kis B, Zeidler J, Klora M, Reese JP, Balzer-Geldsetzer M. Use of antidementia drugs in German patients with Alzheimer’s disease. Int Clin Psychopharmacol. 2018 Mar;33(2):103-110

    M Friedlander J Rau C K Lee W Meier A Lesoin J-W Kim A Poveda M Buck G Scambia M Shimada  F Hilpert M T King P Debruyne A Bolog S Malander B J Monk E Petru P Calvert T J Herzog C Barrett A du Bois. Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters - patient centered endpoints in trials of maintenance therapy. Ann Oncol. 2018 Mar 1;29(3):737-743

    Hessmann P, Dodel R, Baum E, Müller MJ, Paschke G, Kis B, Zeidler J, Klora M, Reese JP, Balzer-Geldsetzer M. Antidepressant medication in a German cohort of patients with Alzheimer's disease. Int J Clin Pharmacol Ther. 2018 Mar;56(3):101-112.

    Björn Tackenberg, Maximilian Schneider, Franz Blaes, Christian Eienbröker, Carmen Schade-Brittinger, Anne Wellek, Marcus Deschauer, Markus Eickmann, Hans-Dieter Klenk, Hans-Helge Müller, Norbert Sommer. Acetylcholine Receptor Antibody Titers and Clinical Course after Influenza Vaccination in Patients with Myasthenia Gravis: A Double-Blind Randomized Controlled Trial (ProPATIent-Trial). EBioMedicine. 2018 Feb;28:143-150

    Kostev K, Von Vultée C, Usinger DM, Reese JP. Tramadol prescription patterns in patients followed by general practitioners and orthopedists in Germany in the year 2015. Postgrad Med. 2018 Jan;130(1):37-41

    Rosner R, Rimane E, Vogel A, Rau J, Hagl, M, et al. Treating prolonged grief disorder with prolonged grief-specific cognitive behavioral therapy: study protocol for a randomized controlled trial. Trials 2018;19(1):241

    Weber-Lassalle K, Harter P, Hauke J, Ernst C, Kommoss S, Marmé F, Weber-Lassalle N, Prieske K, Dietrich D, Borde J, Pohl-Rescigno E, Reuss A, Ataseven B, Engel C, Stingl JC, Schmutzler RK, Hahnen E. Diagnosis of Li-Fraumeni Syndrome: Differentiating TP53 germline mutations from clonal hematopoiesis: Results of the observational AGO-TR1 trial. Hum Mutat. 2018 Dec;39(12):2040-2046.

    Balzer-Geldsetzer M, Ferreira J, Odin P, Bloem BR, Meissner WG, Lorenzl S, Wittenberg M, Dodel R, Schrag A. Study protocol: Care of Late-Stage Parkinsonism (CLaSP): a longitudinal cohort study. BMC Neurol. 2018 Nov 5;18(1):185.

    Mengel D, Fraune L, Sommer N, Stettner M, Reese JP, Dams J, Glynn RJ, Balzer-Geldsetzer M, Dodel R, Tackenberg B. Costs of illness in chronic inflammatory demyelinating polyneuropathy in Germany. Muscle Nerve. 2018 Nov;58(5):681-687.

    Hessmann P, Dodel R, Baum E, Müller MJ, Paschke G, Kis B, Zeidler J, Klora M, Reese JP, Balzer-Geldsetzer M. Antipsychotic treatment of community-dwelling and institutionalised patients with dementia in Germany. Int J Psychiatry Clin Pract. 2018 Sep;22(3):232-239

    Prokosch HU, Acker T, Bernarding J, Binder H, Boeker M, Boerries M, Daumke P, Ganslandt T, Hesser J, Höning G, Neumaier M, Marquardt K, Renz H, Rothkötter HJ, Schade-Brittinger C, Schmücker P, Schüttler J, Sedlmayr M, Serve H, Sohrabi K, Storf H. MIRACUM: Medical Informatics in Research and Care in University Medicine. A Large Data Sharing Network to Enhance Translational Research and Medical Care. Methods Inf Med. 2018 Jul; 57(Suppl 1): e82-e91

    Willems LM, Richter S, Watermann N, Bauer S, Klein KM, Reese JP, Schöffski O, Hamer HM, Knake S, Rosenow F, Strzelczyk A. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany from 2003 to 2013 - A ten-year overview. Epilepsy Behav. 2018 Jun;83:28-35.

  • Inhalt ausklappen Inhalt einklappen Publikationen 2017Publikationen 2017

    Knabe, C., Mele, A., Kann, P. H., Peleska, B., Adel-Khattab, D., Renz, H., Reuss, A., Bohner, M. & Stiller, M. 2017. Effect of sex-hormone levels, sex, body
    mass index and other host factors on human craniofacial bone regeneration with bioactive tricalcium phosphate grafts. Biomaterials, 123(2017)48-62.

    Wilson, M. K., Pujade-Lauraine, E., Aoki, D., Mirza, M. R., Lorusso, D., Oza, A. M., Du Bois, A., Vergote, I., Reuss, A., Bacon, M., Friedlander, M., Gallardo-Rincon, D., Joly, F., Chang, S. J., Ferrero, A. M., Edmondson, R. J., Wimberger, P., Maenpaa, J., Gaffney, D., Zang, R., Okamoto, A., Stuart, G. & Ochiai, K. 2017. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann Oncol, 28(4), 727-732.

    Harter, P., Reuss, A., Sehouli, J., Chiva, L. & Du Bois, A. 2017. Brief Report About the Role of Hyperthermic Intraperitoneal Chemotherapy in a
    Prospective Randomized Phase 3 Study in Recurrent Ovarian Cancer From Spiliotis et al. Int J Gynecol Cancer, 27(2), 246-247.

    Rinke, A., Wittenberg, M., Schade-Brittinger, C., Aminossadati, B., Ronicke, E., Gress, T. M., Muller, H. H., Arnold, R. Placebo Controlled, Double Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results on Long Term Survival. Neuroendocrinology 2017; 104(1): 26-32

    Enders D, Balzer-Geldsetzer M, Riedel O, Dodel R, Wittchen HU, Sensken SC, Wolff B, Reese JP. Prevalence, Duration and Severity of Parkinson’s Disease in Germany: A Combined Meta-Analysis from Literature Data and Outpatient Samples. Eur Neurol 2017;78:128–136

    Harter P, Hauke J, Heitz F, Reuss A, Kommoss S, Marmé F, Heimbach A, Prieske K, Richters L, Burges A, Neidhardt G, de Gregorio N, El-Balat A, Hilpert F, Meier W, Kimmig R, Kast K, Sehouli J, Baumann K, Jackisch C, Park-Simon TW, Hanker L, Kröber S, Pfisterer J, Gevensleben H, Schnelzer A, Dietrich D, Neunhöffer T, Krockenberger M, Brucker SY, Nürnberg P, Thiele H, Altmüller J, Lamla J, Elser G, du Bois A, Hahnen E, Schmutzler R.. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS One. 2017; 12(10)

    Hinderer M, Boeker M, Wagner SA, Binder H, Ückert F, Newe S, Hülsemann JL, Neumaier M, Schade-Brittinger C, Acker T, Prokosch HU, Sedlmayr B. The experience of physicians in pharmacogenomic clinical decision support within eight German university hospitals. 2017 Jun;18(8):773-785

    de Zwaan M, Herpertz S, Zipfel S, Svaldi J, Friederich HC, Schmidt F, Mayr A, Lam T, Schade-Brittinger C, Hilbert A. Effect of Internet-Based Guided Self-help vs Individual Face-to-Face Treatment on Full or Subsyndromal Binge Eating Disorder in Overweight or Obese PatientsThe INTERBED Randomized Clinical Trial. JAMA Psychiatry. 2017 Oct 1;74(10):987-995

    Jacobi C, Beintner I, Fittig E, Trockel M, Braks K, Schade-Brittinger C, Dempfle A. Web-Based Aftercare for Women With Bulimia Nervosa Following Inpatient Treatment: Randomized Controlled Efficacy Trial. J Med Internet Res. 2017 Sep; 19(9)

    Jürgen Behr, Petra Neuser, Antje Prasse, Michael Kreuter, Klaus Rabe, Carmen Schade-Brittinger, Jasmin Wagner and Andreas Günther. Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. BMC Pulmonary Medicine (2017) 17:122

  • Inhalt ausklappen Inhalt einklappen Publikationen 2016Publikationen 2016

    Kurzeder, C., Bover, I., Marme, F., Rau, J., Pautier, P., Colombo, N., Lorusso, D., Ottevanger, P., Bjurberg, M., Marth, C., Barretina-Ginesta, P., Vergote, I., Floquet, A., Del Campo, J. M., Mahner, S., Bastiere-Truchot, L., Martin, N., Oestergaard, M. Z., Kiermaier, A., Schade-Brittinger, C., Polleis, S., Du Bois, A. and Gonzalez-Martin, A. (2016). Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE). Journal of clinical oncology, 34, 2516-2525.

    Gonzalez-Martin, A., Pautier, P., Mahner, S., Rau, J., Colombo, N., Ottevanger, P., Del Campo, J. M., Selle, F., Du Bois, A., Gadducci, A., Garcia, Y., Berton-Rigaud, D., Marme, F., Ortega, E., Martin, N., Bastiere-Truchot, L., Kiermaier, A. and Kurzeder, C. (2016). Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer Safety Run-in Results of the PENELOPE Trial. International Journal of Gynecological Cancer 26, 898-905. 

    Andreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, Alexander Reuss, Sandro Pignata, Nicoletta Colombo, Ursula Denison, Ignace Vergote, Jose M del Campo, Petronella Ottevanger, Martin Heubner, Thomas Minarik, Emmanuel Sevin, Nikolaus de Gregorio, Mariusz Bidziński, Jacobus Pfisterer, Susanne Malander, Felix Hilpert, Mansoor R Mirza, Giovanni Scambia, Werner Meier, Maria O Nicoletto, Line Bjørge, Alain Lortholary, Martin Oliver Sailer, Michael Merger, Philipp Harter, on behalf of the AGO Study Group led Gynecologic Cancer Intergroup (GCIG)/ European Network of Gynaecologic Oncology Trials Groups (ENGOT) Intergroup ConsortiumMDt, Prof Giovanni Scambia, MDu, Prof Werner Meier, MDv. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2016; 17: 78–89

    Sagae S, Monk BJ, Pujade-Lauraine E, Gaffney DK, Narayan K, Ryu SY, McCormack M, Plante M, Casado A, Reuss A, Chávez-Blanco A, Kitchener H, Nam BH, Jhingran A, Temkin S, Mileshkin L, Berns E, Scholl S, Doll C, Abu-Rustum. Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future. Int J Gynecol Cancer. 2016 Jan;26(1):199-207

    Maria Kleinstäuber, Japhia Gottschalk, Matthias Berking, Jörn Rau, Winfried Rief. Enriching Cognitive Behavior Therapy with Emotion Regulation Training for Patients with Multiple Medically Unexplained Symptoms (ENCERT): Design and implementation of a multicenter, randomized, active-controlled trial. Contemporary Clinical Trials 47 (2016) 54–63

    Teymoortash A, Pfestroff A, Wittig A, Franke N, Hoch S, Harnisch S, Schade-Brittinger C, Hoeffken H, Engenhart-Cabillic R, Brugger M, Strauch K. Safety and Efficacy of Botulinum Toxin to Preserve Gland Function after Radiotherapy in Patients with Head and Neck Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blinded Phase I Clinical Trial. PLoS One. 2016 Mar 18;11(3)

    Emons G, Kurzeder C, Schmalfeldt B, Neuser P, de Gregorio N, Pfisterer J, Park-Simon TW, Mahner S, Schröder W, Lück HJ, Heubner ML, Hanker L, Thiel F, Hilpert F.: Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8). Gynecol Oncol. 2016 Mar;140(3):450-6.

    Mengel D, Dams J, Ziemek J, Becker J, Balzer-Geldsetzer M, Hilker R, Baudrexel S, Kalbe E, Schmidt N, Witt K, Liepelt-Scarfone I, Gräber S, Petrelli A, Neuser P, Schulte C, Linse K, Storch A, Wittchen HU, Riedel O, Mollenhauer B, Ebentheuer J, Trenkwalder C, Klockgether T, Spottke A, Wüllner U, Schulz JB, Reetz K, Heber IA, Ramirez A, Dodel R. Apolipoprotein E ε4 does not affect cognitive performance in patients with Parkinson's disease. Parkinsonism Relat Disord. 2016 Aug; 29:112–116.

    M. Klar, A. Hasenburg, M. Hasanov, F. Hilpert, W. Meier, J. Pfisterer, E. Pujade-Lauraine, J. Herrstedt, A. Reuss, A. du Bois: Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer 2016 Oct; 66:114-124.

    Jacek P. Grabowski,  Philipp Harter, Florian Heitz, Eric Pujade-Lauraine, Alexander Reuss, Gunnar Kristensen, Isabelle Ray-Coquard, Julia Heitz, Alexander Traut, Jacobus Pfisterer, Andreas du Bois: Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecologic Oncology 2016 Mar; 140(3):457–462

    Eulenburg, C., Suling, A., Neuser, P., Reuss, A., Canzler, U., Fehm, T., Luyten, A., Hellriegel, M., Woelber, L. & Mahner, S. 2016. Propensity Scoring after Multiple Imputation in a Retrospective Study on Adjuvant Radiation Therapy in Lymph-Node Positive Vulvar Cancer. PLoS One, 11(11);

    Harter, P., Sehouli, J., Reuss, A., Baumann, K., Hanker, L., Kimmig, R., Schroder, W., Burges, A., Gropp-Meier, M., Kurzeder, C., Mahner, S., Canzler, U., Luck, H. J., Meier, W., Fehm, T. & Du Bois, A. 2016. Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7). Int J Gynecol Cancer, 26(9), 1636-1641.

    Woelber, L., Griebel, L.-F., Eulenburg, C., Sehouli, J., Jueckstock, J., Hilpert, F., De Gregorio, N., Hasenburg, A., Ignatov, A., Hillemanns, P., Fuerst, S., Strauss, H.-G., Baumann, K. H., Thiel, F. C., Mustea, A., Meier, W., Harter, P., Wimberger, P., Hanker, L. C., Schmalfeldt, B., Canzler, U., Fehm, T., Luyten, A., Hellriegel, M., Kosse, J., Heiss, C., Hantschmann, P., Mallmann, P., Tanner, B., Pfisterer, J., Richter, B., Neuser, P. & Mahner, S. 2016. Role of tumour-free margin distance for loco-regional control in vulvar cancer—a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter study. European Journal of Cancer, 69;180-188.

  • Inhalt ausklappen Inhalt einklappen Publikationen 2015Publikationen 2015

    Du Bois, A., Reuss, A., Pujade-Lauraine, E., Pignata, S., Ledermann, J., Casado, A., Sehouli, J., Mirza, M., Colombo, N., Marth, C., Witteveen, E., Del Campo, J., Calvert, P., Aravantinos, G., Vardar, M. A., Van Der Zee, A. G., Korach, J., Taskiran, C., Fehr, M., Glasspool, R., Pfisterer, J., Cibula, D. & Vergote, I. 2015. European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners-First Update 2015. Int J Gynecol Cancer.

    Farthmann, J., Hasenburg, A., Weil, M., Fotopoulou, C., Ewald-Riegler, N., Du Bois, O., Trillsch, F., Mahner, S., Strauss, H. G., Wimberger, P., Reuss, A. & Du Bois, A. 2015. Quality of life and sexual function in patients with borderline tumors of the ovary. A substudy of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group ROBOT study. Support Care Cancer, 23(1), 117-23.

    Fotopoulou, C., Sehouli, J., Ewald-Riegler, N., De Gregorio, N., Reuss, A., Richter, R., Mahner, S., Kommoss, F., Schmalfeldt, B., Fehm, T., Hanker, L., Wimberger, P., Canzler, U., Pfisterer, J., Kommoss, S., Hauptmann, S. & Du Bois, A. 2015. The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study. Int J Gynecol Cancer.

    Mahner, S., Jueckstock, J., Hilpert, F., Neuser, P., Harter, P., De Gregorio, N., Hasenburg, A., Sehouli, J., Habermann, A., Hillemanns, P., Fuerst, S., Strauss, H. G., Baumann, K., Thiel, F., Mustea, A., Meier, W., Du Bois, A., Griebel, L. F. & Woelber, L. 2015. Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. J Natl Cancer Inst, 107(3).

    Sehouli, J., Fotopoulou, C., Erol, E., Richter, R., Reuss, A., Mahner, S., Lauraine, E. P., Kristensen, G., Herrstedt, J., Du Bois, A. & Pfisterer, J. 2015. Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients. Eur J Cancer, 51(7), 825-32.

    Stamelou, M., Pilatus, U., Reuss, A., Respondek, G., Knake, S., Oertel, W. H. & Hoglinger, G. U. 2015. Brain energy metabolism in early MSA-P: A phosphorus and proton magnetic resonance spectroscopy study. Parkinsonism Relat Disord, 21(5), 533-5.

    Trillsch, F., Mahner, S., Vettorazzi, E., Woelber, L., Reuss, A., Baumann, K., Keyver-Paik, M. D., Canzler, U., Wollschlaeger, K., Forner, D., Pfisterer, J., Schroeder, W., Muenstedt, K., Richter, B., Fotopoulou, C., Schmalfeldt, B., Burges, A., Ewald-Riegler, N., De Gregorio, N., Hilpert, F., Fehm, T., Meier, W., Hillemanns, P., Hanker, L., Hasenburg, A., Strauss, H. G., Hellriegel, M., Wimberger, P., Kommoss, S., Kommoss, F., Hauptmann, S. & Du Bois, A. 2015. Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study. Br J Cancer, 112(4), 660-6.

    Thomas M, Fischer J, Andreas S, Kortsik C, Grah C, Serke M, von Eiff M, Witt C, Kollmeier J, Müller E, Schenk M, Schröder M, Villalobos M, Reinmuth N, Penzel R, Schnabel P, Acker T, Reuss A, Wolf M; ABC-Lung Cancer Group. Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer.
    Eur Respir J. 2015 Jul;46(1):219-29.

    Poveda AM, Selle F, Hilpert F, Reuss A, Savarese A, Vergote I, Witteveen P, Bamias A, Scotto N, Mitchell L, Pujade-Lauraine E. Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial
    J Clin Oncol. 2015 Nov 10;33(32):3836-8.

  • Inhalt ausklappen Inhalt einklappen Publikationen 2014Publikationen 2014

    Du Bois, A., Floquet, A., Kim, J. W., Rau, J., Del Campo, J. M., Friedlander, M., Pignata, S., Fujiwara, K., Vergote, I., Colombo, N., Mirza, M. R., Monk, B. J., Kimmig, R., Ray-Coquard, I., Zang, R., Diaz-Padilla, I., Baumann, K. H., Mouret-Reynier, M. A., Kim, J. H., Kurzeder, C., Lesoin, A., Vasey, P., Marth, C., Canzler, U., Scambia, G., Shimada, M., Calvert, P., Pujade-Lauraine, E., Kim, B. G., Herzog, T. J., Mitrica, I., Schade-Brittinger, C., Wang, Q., Crescenzo, R. & Harter, P. 2014. Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer. J Clin Oncol. , 32 (30), 374-82.

    Funck, R. C., Mueller, H. H., Lunati, M., Piorkowski, C., De Roy, L., Paul, V., Wittenberg, M., Wuensch, D. & Blanc, J. J. 2014. Characteristics of a large sample of candidates for permanent ventricular pacing included in the Biventricular Pacing for Atrio-ventricular Block to Prevent Cardiac Desynchronization Study (BioPace). Europace, 16(3), 354-62.

    Herpertz-Dahlmann, B., Schwarte, R., Krei, M., Egberts, K., Warnke, A., Wewetzer, C., Pfeiffer, E., Fleischhaker, C., Scherag, A., Holtkamp, K., Hagenah, U., Buhren, K., Konrad, K., Schmidt, U., Schade-Brittinger, C., Timmesfeld, N. & Dempfle, A. 2014. Day-patient treatment after short inpatient care versus continued inpatient treatment in adolescents with anorexia nervosa (ANDI): a multicentre, randomised, open-label, non-inferiority trial. Lancet, 383(9924), 1222-9.

    Maschuw, K., Heinz, C., Maurer, E., Reuss, A., Schade-Brittinger, C. & Bartsch, D. K. 2014. Intracutaneous suture versus transcutaneous skin stapling for closure of midline or horizontal skin incision in elective abdominal surgery and their outcome on superficial surgical site infections--INTRANS: study protocol for a randomized controlled trial. Trials, 1525.

    Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., Sorio, R., Vergote, I., Witteveen, P., Bamias, A., Pereira, D., Wimberger, P., Oaknin, A., Mirza, M. R., Follana, P., Bollag, D. & Ray-Coquard, I. 2014. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol, 32(13), 1302-8.

    Schäpbach, W. M. M.*, Rau, J.*, Houeto, J.-L., Krack, P., Schnitzler, A., Schade-Brittinger, C., Timmermann, L. & Deuschl, G. 2014. Myths and Facts About the EARLYSTIM Study. Movement Disorders, Vol. 29, No. 14, 1742-50. (*equally contributed)

    Trillsch, F., Mahner, S., Woelber, L., Vettorazzi, E., Reuss, A., Ewald-Riegler, N., De Gregorio, N., Fotopoulou, C., Schmalfeldt, B., Burges, A., Hilpert, F., Fehm, T., Meier, W., Hillemanns, P., Hanker, L., Hasenburg, A., Strauss, H. G., Hellriegel, M., Wimberger, P., Baumann, K., Keyver-Paik, M. D., Canzler, U., Wollschlaeger, K., Forner, D., Pfisterer, J., Schroeder, W., Muenstedt, K., Richter, B., Kommoss, F., Hauptmann, S. & Du Bois, A. 2014. Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study. Ann Oncol, 25(7), 1320-7.

    Zipfel, S., Wild, B., Gross, G., Friederich, H. C., Teufel, M., Schellberg, D., Giel, K. E., De Zwaan, M., Dinkel, A., Herpertz, S., Burgmer, M., Lowe, B., Tagay, S., Von Wietersheim, J., Zeeck, A., Schade-Brittinger, C., Schauenburg, H. & Herzog, W. 2014. Focal psychodynamic therapy, cognitive behaviour therapy, and optimised treatment as usual in outpatients with anorexia nervosa (ANTOP study): randomised controlled trial. Lancet, 383(9912), 127-37.

  • Inhalt ausklappen Inhalt einklappen Publikationen 2013Publikationen 2013

    Bauerschlag, D. O., Hilpert, F., Meier, W., Rau, J., Meinhold-Heerlein, I., Maass, N., Dubois, A., Sehouli, J., Arnold, N., Schem, C., Oberg, H. H. & Baumann, K. 2013. Evaluation of potentially predictive markers for anti-angiogenic therapy with sunitinib in recurrent ovarian cancer patients. Transl Oncol. 2013 Jun 1;6(3):305-10

    Deuschl, G., Schupbach, M., Knudsen, K., Pinsker, M. O., Cornu, P., Rau, J., Agid, Y. & Schade-Brittinger, C. 2013. Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: concept and standards of the EARLYSTIM-study. Parkinsonism Relat Disord, 19(1), 56-61.

    Dodel, R., Schade-Brittinger, C. & Diener, H. C. 2013. Worauf kommt es beim Lesen von Therapiestudien an? Akt Neurol, 36(01), 22-28.

    du Bois, A., Ewald-Riegler, N., De Gregorio, N., Reuss, A., Mahner, S., Fotopoulou, C., Kommoss, F., Schmalfeldt, B., Hilpert, F., Fehm, T., Burges, A., Meier, W., Hillemanns, P., Hanker, L., Hasenburg, A., Strauss, H. G., Hellriegel, M., Wimberger, P., Keyver-Paik, M. D., Baumann, K., Canzler, U., Wollschlaeger, K., Forner, D., Pfisterer, J., Schroder, W., Munstedt, K., Richter, B., Kommoss, S. & Hauptmann, S. 2013. Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) Study Group. Eur J Cancer. 2013 Mar 11, 49, 1905-1914

    Fensterer, H., Schade-Brittinger, C., Muller, H. H., Tebbe, S., Fass, J., Lindig, U., Settmacher, U., Schmidt, W. E., Marten, A., Ebert, M. P., Kornmann, M., Hofheinz, R., Endlicher, E., Brendel, C., Barth, P. J., Bartsch, D. K., Michl, P. & Gress, T. M. 2013. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP). Ann Oncol. 2013 Oct;24(10):2576-81

    Harter, P., Sehouli, J., Kimmig, R., Rau, J., Hilpert, F., Kurzeder, C., Elser, G. & Du Bois, A. 2013. Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13). Invest New Drugs (2013) 31:1499–1504.

    Mahner, S., Eulenburg, C., Staehle, A., Wegscheider, K., Reuss, A., Pujade-Lauraine, E., Harter, P., Ray-Coquard, I., Pfisterer, J. & Du Bois, A. 2013. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. Eur J Cancer, 49(1), 142-9.

    Schuepbach, W. M. M*., Rau, J*., Knudsen, K*., Volkmann, J., Krack, P., Timmermann, L., Hälbig, T. D., Hesekamp, H., Navarro, S. M., Meier, N., Falk, D., Mehdorn, M., Paschen, S., Maarouf, M., Barbe, M. T., Fink, G. R., Kupsch, A., Gruber, D., Schneider, G.-H., Seigneuret, E., Kistner, A., Chaynes, P., Ory-Magne, F., Brefel Courbon, C., Vesper, J., Schnitzler, A., Wojtecki, L., Houeto, J.-L., Bataille, B., Maltäte, D., Damier, P., Raoul, S., Sixel-Doering, F., Hellwig, D., Gharabaghi, A., Krüger, R., Pinsker, M. O., Amtage, F., Rägis, J.-M., Witjas, T., Thobois, S., Mertens, P., Kloss, M., Hartmann, A., Oertel, W. H., Post, B., Speelman, H., Agid, Y.*, Schade-Brittinger, C.* & Deuschl, G.* 2013. Neurostimulation for Parkinson's Disease with Early Motor Complications. New England Journal of Medicine, 368(7), 610-622. (*shared authorship)

    Zipfel S, Wild B, Groߟ G, Friederich HC, Teufel M, Schellberg D, Giel KE, de Zwaan M, Dinkel A, Herpertz S, Burgmer M, Läwe B, Tagay S, von Wietersheim J, Zeeck A, Schade-Brittinger C, Schauenburg H, Herzog W. Focal psychodynamic therapy, cognitive behaviour therapy, and optimised treatment as usual in outpatients with anorexia nervosa (ANTOP study): randomised controlled trial. The Lancet 14 October 2013 (Article in Press DOI: 10.1016/S0140-6736(13)61746-8)

    Deuschl G, Schade-Brittinger C, Agid Y. 2013 Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. May 23;368(21):2038. (letter)

    Heitz F, du Bois A, Harter P, Lubbe D, Kurzeder C, Vergote I, Plante M, Pfisterer J. 2013. Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG. Gynecol Oncol. 2013 Jun;129(3):463-6

    Swierkot K, Brusius M, Leismann D, Nonnenmacher C, Nüsing R, Lubbe D, Schade-Brittinger C, Mengel R. 2013 Manual versus sonic-powered toothbrushing for plaque reduction in patients with dental implants: an explanatory randomised controlled trial. Eur J Oral Implantol. 2013;6(2):133-44.

    Ohmann C, Canham S, Cornu C, DreŸ J, Gueyffier F, Kuchinke W, Nicolis EB, Wittenberg M. Revising the ECRIN standard requirements for information technology and data management in clinical trials. Trials 2013, 14:97. Open access: http://www.trialsjournal.com/content/14/1/97


    Funck RC, Mueller HH, Lunati M, Piorkowski C, De Roy L, Paul V, Wittenberg M, Wuensch D, Blanc JJ; for the BioPace study group. Characteristics of a large sample of candidates for permanent ventricular pacing included in the Biventricular Pacing for Atrio-ventricular Block to Prevent Cardiac Desynchronization Study (BioPace). Europace. 2013 Nov 7. [Epub ahead of print]

    Arnold R, Wittenberg M, Rinke A, Schade-Brittinger C, Aminossadati B, Ronicke E, Gress TM, Mueller HH, PROMID Study Group. Placebo controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): Results on long-term survival. J Clin Oncol 31, 2013 (suppl; abstr 4030)

  • Inhalt ausklappen Inhalt einklappen Publikationen 2012Publikationen 2012

    Deuschl G, Schäpbach M, Knudsen K, Pinsker MO, Cornu P, Rau J, Agid Y, Schade-Brittinger C. Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: Concept and standards of the EARLYSTIM-study. Parkinsonism Relat Disord. 2012 Jul 28. [Epubaheadofprint].

    Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardiäre C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Müller HH, Skogseid B. Combination Chemotherapy in Advanced Adrenocortical Carcinoma. N Engl J Med. 2012 Jun 7;366(23):2189-97.

    Rosenow F, Schade-Brittinger C, Burchardi N, Bauer S, Klein KM, Weber Y, Lerche H, Evers S, Kovac S, Hallmeyer-Elgner S, Winkler G, Springub J, Niedhammer M, Roth E, Eisensehr I, Berrouschot J, Arnold S, Schräder M, Beige A, Oertel WH, Strzelczyk A, Haag A, Reif PS, Hamer HM; fortheLaLiMo Study Group. The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy--an open-label, prospective, randomised controlled multicenter study.. J NeurolNeurosurg Psychiatry, Epub 2012 May 17.

    Harnisch S, Schade-Brittinger C, Rief W. Erfassung von Nebenwirkungen in der klinischen Forschung. Dtsch Med Wochenschr. 2012 Jul;137(27):1421-5.

    Meier W, du Bois A, Rau J, Gropp-Meier M, Baumann K, Huober J, Wollschlaeger K, Kreienberg R, Canzler U, Schmalfeldt B, Wimberger P, Richter B, Schräder W, Belau A, Stähle A, Burges A, Sehouli J. Randomizedphase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV. Gynecol Oncol. 2012 Aug;126(2):236-40.

    Wiegard K, Albert US, Zemlin C, Lubbe D, Kleiber C, Kolb-Niemann B, Schade-Brittinger C, Wagner U, Herrmann-Lingen C. Psychological distress of breast cancer patients: screening and patients' request for psycho-oncological care as indicators of health-related quality of life. PsychotherPsychosom Med Psychol. 2012 Mar-Apr;62(3-4):129-35. Epub 2012 Apr 2. German.

    Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, Ray-Coquard I, Sehouli J, Harter P, du Bois A; on behalf of the AGO and GINECO study group. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/ platinum-based therapy. Ann Oncol. 2012 Aug 21. [Epub ahead of print]

    Baumann KH, du Bois A, Meier W, Rau J, Wimberger P, Sehouli J, Kurzeder C, Hilpert F, Hasenburg A, Canzler U, Hanker LC, Hillemanns P, Richter B, Wollschlaeger K, Dewitz T, Bauerschlag D, Wagner U. A phase II trial (AGO 2.11) in platinum-resistant ovarian ancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine inase inhibitor monotherapy. Ann Oncol. 2012 Sep;23(9):2265-71

  • Inhalt ausklappen Inhalt einklappen Publikationen 2011Publikationen 2011

    Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 2011;21(2):289-95.

    Larisch A, Reuss A, Oertel WH, Eggert K. Does the clinical practice guideline on Parkinson's disease change health outcomes? A cluster randomized controlled trial. J Neurol 2011;258(5):826-34.

    Ohmann C, Kuchinke W, Canham S, Lauritsen J, Salas N, Schade-Brittinger C, Wittenberg M, et al. Standard requirements for GCP-compliant data management in multinational clinical trials. Trials 2011;12(1):85.

    Stamelou M, Christ H, Reuss A, Oertel W, Hoglinger G. Hypodipsia discriminates progressive supranuclear palsy from other parkinsonian syndromes. Mov Disord 2011;26(5):901-5.

  • Inhalt ausklappen Inhalt einklappen Publikationen - ArchivPublikationen - Archiv

    2010 ||| 2009 ||| 2008 ||| 2007 ||| 2006 ||| 2005 ||| 2004 ||| 2003 ||| 2002 ||| 2001 ||| 1999

    2010

    Käbel M, Reuss A, Bois A, Kommoss S, Kommoss F, Gao D, et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol 2010;222(2):191-8.

    Dodel R, Spottke A, Gerhard A, Reuss A, Reinecker S, Schimke N, et al. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord 2010;25(1):97-107.

    du Bois A, Herrstedt J, Hardy-Bessard AC, Müller HH, Harter P, Kristensen G, et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol 2010;28(27):4162-9.

    du Bois A, Reuss A, Harter P, Pujade-Lauraine E, Ray-Coquard I, Pfisterer J. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol 2010;28(10):1733-9.

    Kuchinke W, Ohmann C, Yang Q, Salas N, Lauritsen J, Gueyffier F, Leizorovicz A, Schade-Brittinger C, Wittenberg M, et al. Heterogeneity prevails: the state of clinical trial data management in Europe - results of a survey of ECRIN centres. Trials 2010;11:79.

    Mackay HJ, Brady MF, Oza AM, Reuss A, Pujade-Lauraine E, Swart AM, et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 2010;20(6):945-52.

    Menzler K, Chen X, Thiel P, Iwinska-Zelder J, Miller D, Reuss A, et al. Epileptogenicity of cavernomas depends on (archi-) cortical localization. Neurosurgery 2010;67(4):918-24.

    2009

    de Zwaan M, Zipfel S, Herzog W, Herpertz-Dahlmann B, Konrad K, Hebebrand J, Schade-Brittinger C, Schäfer H, Fichter M, Quadflieg N, Jacobi C, Herpertz S. [EDNET - eating disorders diagnostic and treatment network]. Psychother Psychosom Med Psychol. Mar-Apr 2009;59(3-4):110-116.

    du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. Mar 15 2009;115(6):1234-1244.

    Harter P, Hahmann M, Lueck HJ, et al. Surgery for Recurrent Ovarian Cancer: Role of Peritoneal Carcinomatosis: Exploratory Analysis of the DESKTOP I Trial About Risk Factors, Surgical Implications, and Prognostic Value of Peritoneal Carcinomatosis. Annals of Surgical Oncology. May 2009;16(5):1324-1330.

    Meier W, du Bois A, Reuss A, et al. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecologic Oncology. Aug 2009;114(2):199-205.

    Pfisterer J, du Bois A, Bentz EK, Kommoss F, Harter P, Huober J, Schmalfeldt B, Burchardi N, Arnold N, Hilpert F. Prognostic Value of Human Epidermal Growth Factor Receptor 2 (Her-2)/neu in Patients With Advanced Ovarian Cancer Treated With Platinum/Paclitaxel as First-Line Chemotherapy: A Retrospective Evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany. International Journal of Gynecological Cancer. Jan 2009;19(1):109-115.

    Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. Oct 1 2009;27(28):4656-4663.

    Stamelou M, Pilatus U, Reuss A, et al. In vivo evidence for cerebral depletion in high-energy phosphates in progressive supranuclear palsy. Journal of Cerebral Blood Flow and Metabolism. Apr 2009;29(4):861-870.

    Wild B, Friederich HC, Gross G, Teufel M, Herzog W, Giel KE, de Zwaan M, Schauenburg H, Schade-Brittinger C, Schäfer H, Zipfel S. The ANTOP study: focal psychodynamic psychotherapy, cognitive-behavioural therapy, and treatment-as-usual in outpatients with anorexia nervosa--a randomized controlled trial. Trials. 2009;10:23.

    2008

    Arnold R, Wilke A, Rinke A, Mayer C, Kann PH, Klose KJ, Scherag A, Hahmann M, Müller HH, Barth P. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol. 2008;6(7):820-827.

    Fotopoulou C, du Bois A, Karavas AN, Trappe R, Aminossadati B, Schmalfeldt B, Pfisterer J, Sehouli J. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. J Clin Oncol. 2008;26(16):2683-2689.

    Harter P, Reuss A, Pfisterer J, Pujade-Lauraine E, Ray I, du Bois A. The role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer. A project of the AGO-OVAR and GINECO - Prognostic factor surgical outcome in advanced ovarian cancer. Geburtshilfe Und Frauenheilkunde. Sep 2008;68:S9-S10.

    Stamelou M, Reuss A, Pilatus U, et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord. 2008;23(7):942-949.

    2007

    Belau A, Pfisterer J, Wimberger P, Kurzeder C, du Bois A, Sehouli J, Loibl S, Burchardi N, Vergote I, Wagner U. Randomized, multicenter, two-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM × anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer. Journal of Clinical Oncology. 2007;25(June 20):5556.

    du Bois A, Pfisterer J, Burchardi N, et al. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K. Gynecol Oncol. 2007;107(3):518-525.

    Haake M, Mueller HH, Schade-Brittinger C, et al. German Acupuncture Trials (GERAC) for Chronic Low Back Pain: Randomized, Multicenter, Blinded, Parallel-Group Trial With 3 Groups. Arch Intern Med. 2007;167(17):1892-1898.

    Hahmann M, Schuster S, Peters R, Butterfa-Bahloul T. MedDRA-Kodierung von Studiendaten; in: Kongress Medizin und Gesellschaft 2007 a€“ Abstractband,
    Hrsg: Wichmann HE, Nowak D, Zapf A; Augsburg, 2007, S. 112.

    Seifart U, Fink T, Schade-Brittinger C, et al. Randomised phase II study comparing topotecan/carboplatin administration for 5 versus 3 days in the treatment of extensive-stage small-cell lung cancer. Ann Oncol. 2007;18(1):104-109.

    2006

    Deuschl, G.; Schade-Brittinger, C.; Krack, P.; Volkmann, J.; Schafer, H.; Botzel, K.; Daniels, C.; Deutschlander, A.; Dillmann, U.; Eisner, W.; Gruber, D.; Hamel, W.; Herzog, J.; Hilker, R.; Klebe, S.; Kloss, M.; Koy, J.; Krause, M.; Kupsch, A.; Lorenz, D.; Reuss, f. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006;355(9):896-908.

    Chen X, Heinze S, Iwinska-Zelder J, Reuss A et al. Risk factors for epilepsy in patients with cavernomas. Akt Neurol. 2006:33.

    Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006;355(9):896-908.

    du Bois A, Reuss A, Harter P, Meier W, et al. The role of lymphadenectomy in advanced epithelial ovarian cancer in patients with macroscopically complete resection of intraperitoneal disease. Int J Gynecol Cancer. 2006;16(S3):601; #0008.

    du Bois A, Weber B, Rochon J, et al. Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study. Journal of Clinical Oncology. 2006;24(7):1127-1135.

    Funck RC, Blanc J-J, Mueller HH, Schade-Brittinger C, Bailleul C, Maisch B. Biventricular stimulation to prevent cardiac desynchronization: rationale, design, and endpoints of the 'Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization (BioPace)' study. Europace. 2006;8(8):629-635.

    Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13(12):1702-1710.

    Knake S, Rochon J, Fleischer S, et al. Status Epilepticus after Stroke Is Associated with Increased Long-term Case Fatality. Epilepsia. 2006;47 Dec(12):2020-2026(2027).

    Ohmann C, Speer R, Wittenberg M, Semler SC, Drepper J. Strategie und Ausbau der IT-Infrastruktur für die medizinische Verbundforschung in Deutschland; in: GMDS 51. Jahrestagung 2006 – Abstractband, Leipzig, 2006, S. 104-105.

    Ozols RF, Bookman MA, du Bois A, Pfisterer J, Reuss A, Young RC. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol. 2006;103(1):1-6.

    Pfisterer J, du Bois A, Sehouli J, Loibl S, Reinartz S, Reuss A, Canzler U, Belau A, Jackisch C, Kimmig R, Wollschlaeger K, Heilmann V, Hilpert F. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol. 2006;17(10):1568-1577.

    Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24(29):4699-4707.

    Pfisterer J, Weber B, Reuss A, et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute. 2006;98(15):1036-1045.

    Wittenberg M, Speer R, Kuchinke W, et al. Erreichung und Sicherstellung von Validierungsstandards in den Forschungsverbünden der Telematikplattform für Medizinische Forschungsnetze e.V. (TMF); in: GMDS 51. Jahrestagung 2006 – Abstractband, Leipzig, 2006, S. 193.

    2005

    Arnold R, Rinke A, Klose KJ, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol. 2005;3(8):761-771.

    Donner-Banzhoff N, Brucks U, Schade-Brittinger C, Muller H-H. Long-term benefits of a postgraduate programme in clinical epidemiology. The study programme ''clinical evaluation'' of the University of Marburg. Z Arztl Fortbild Qualitatssich. 2005;99(7):449-454.

    du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005;16 Suppl 8:viii7-viii12.

    du Bois A, Rochon J, Lamparter C, Pfisterer J. Das Qualitätsprogramm der AGO Organkommission OVAR (QS-OVAR): Versorgungsstruktur und Realität 2001. Zentralbl Gynäkol. 2005;127:9-17.

    du Bois A, Rochon J, Lamparter C, Pfisterer J. Impact of center characteristics on outcome in ovarian cancer in Germany. Zentralbl Gynakol. 2005;127 Feb(1):18-30.

    du Bois A, Rochon J, Lamparter C, Pfisterer J. Ovarialkarzinom - Versorgungsstruktur und -qualität in Deutschland 2001-2004. Frauenarzt. 2005;7:560-567.

    du Bois A, Rochon J, Lamparter C, Pfisterer J. Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer. 2005;15(2):183-191.

    du Bois A, Rochon J, Lamparter C, Pfisterer J. Welchen Einfluss haben Klinikmerkmale auf die Prognose beim Ovarialkarzinom in Deutschland? Zentralbl Gynäkol. 2005;127(18-30).

    du Bois A, Sehouli J, Lund B, et al. Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicentre phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) compar. Int J Gynecol Cancer. 2005;15(Suppl.3):224-225.

    Harder S, Fischer P, Krause-Schafer M, et al. Structure and markers of appropriateness, quality and performance of drug treatment over a 1-year period after hospital discharge in a cohort of elderly patients with cardiovascular diseases from Germany. Eur J Clin Pharmacol. 2005;60(11):797-805.

    Harter P, du Bois A, Schade-Brittinger C, et al. Non-enrolment of ovarian cancer patients in clinical trials: reasons and background. Annals of Oncology. 2005;16 Nov(11):763-770.

    Hilpert F, Harter P, Reinartz S, et al. Phase I/II trial of the anti-idiotypic monoclonal antibody CA125 in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer. Journal of Clinical Oncology. 2005;23(S16):5018.

    Nonnenmacher C, Dalpke A, Rochon J, Flores-de-Jacoby L, Mutters R, Heeg K. Real-time polymerase chain reaction for detection and quantification of bacteria in periodontal patients. J Periodontol. 2005;76(9):1542-1549.

    Pfisterer J, Harter P, Canzler U, et al. The role of surgery in recurrent ovarian cancer. Int J Gynecol Cancer. 2005;15(S3):195-198.

    Pfisterer J, Weber B, du Bois A, et al. Paclitaxel/Carboplatin (TC) vs. Paclitaxel/Carboplatin followed by Topotecan (TOP) in First-Line Treatment of Advanced Ovarian Cancer. Mature Results of a Gynecological Cancer Intergroup Phase III Trial of the AGO OVAR and GINECO. 2005;23(16S Part I of II):#5007.

    Pujade-Lauraine E, du Bois A, Goupil A, et al. Epirubicin/ paclitaxel/ carboplatin (TEC) vs paclitaxel/ carboplatin (TC) in first-line treatment of ovarian cancer FIGO stages IIB-IV. Results of a randomized AGO-GINECO GCIG Intergroup phase III trial. Int J Gynecol Cancer. 2005;15(S3):221.

    Schade-Brittinger C. Einbindung eines KKS in ein Comprehensive Cancer Center; Philipps-Universität Marburg, Symposium 2005.

    Stuart G, Avall-Lundqvist E, du Bois A, et al. 3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration. Annals of Oncology. 2005;16(S8):viii36-viii38.

    Vermorken JB, Parmar MKB, Brady MF, et al. Clinical trials in ovarian carcinoma: study methodology. Annals of Oncology. 2005;16(S8):viii20 - viii29.

    2004

    du Bois A, Fink D, Schroeder W, Muenstedt K, Schmalfeldt B, Emmons G, Pfisterer J, Wollschlaeger K, Meerpohl HG, Hahmann M, Harter P. Descriptive Evaluation of pre-operative Selektion KriTeria for OPerability in recurrent OVARian cancer (DESKTOP-OVAR). A study of the AGO Ovarian Cancer Study Group and the AGO Organkommission Ovar. 2004. Int J Gynecol Cancer 2004, 14 (Suppl.1), 17 Abstract # 055. IGCS 2004 Oral Presentation

    Gropp M, Meier W, Rochon J, du Bois A, Kuhn W, Pfisterer J, Richter B, Wollschlaeger K. Topotecan versus Treosulfan beim rezidivierten Ovarialkarzinom: Ergebnisse der Studie Ovar 2.3 der AGO Studiengruppe Ovarialkarzinom. 2004.

    Höglinger GU, Rissling I, Metz A, Ries V, Heinermann A, Prinz H, Spieker S, Deuschl G, Baum E, Oertel WH, "Enhancing Recognition of Early Parkinsonism in the Community," Movement Disorder, Vol. 19, No. 5, 2004, pp. 505-512.

    Harter P, Schade-Brittinger C, Burges A, Wollschlaeger K, Gropp M, Pfisterer J, Schmalfeldt B, Huober J, Staehle A, du Bois A. AGO-OVAR 14: A retrospective study evaluating the reasons for non-participating in trials in patients with ovarian cancer (OC) treated in coordinating centres of the AGO Studiengruppe Ovarialkarzinom. 2004. J Cancer Res Clin Oncol 130 Suppl. 1: 2004.

    Harter P, Schade-Brittinger C, Belau A, Sehouli J, Loibl S, Lueck HJ, Jackisch C, Schroeder W, Canzler U, Kimmig R. AGO-OVAR 14: A restrospective study evaluating the reasons for non-participating in trials in patients with ovarian cancer (OG) treated in coordinating centers of the AGO Ovarian Cancer Study Group. 2004. Proc Am Soc Clin Oncol 23 2004, Abstract # 5081.

    Harter P, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, du Bois A. AGO-DESKTOP-OVAR: Deskriptive Evaluation präoperativer Selektions-Kriterien für die Operabilität bei rezidiviertem Ovarialkarzinom. 2004. Arch Gynecol Obstet, 270, 2004, 2 FV-O 1.8.

    Kuchinke W, Venesileas D, Wagner M, Peters R, Wittenberg M, Bratke T, Meissner C, Ohmann C. Evaluation der Anwendung und Nutzerzufriedenheit mit Electronic Data Capture an sieben Koordinierungszentren für Klinische Studien (KKS). GMDS Jahrestagung . 2004. Abstract

    2003

    Schade-Brittinger C. Koordinierungszentren für klinische Studien. Kongress Klinische Studien in der Neurologie . 2003. Abstract

    Wittenberg M. EDC-Software in akademischen Institutionen, MACRO am KKS Marburg. MEDICA . 2003.

    Diener H.C., Weber R., Schade-Brittinger C, and et.al.. Klinische Studien im Bereich der Neurologie in Deutschland. 2004. Akt. Neurol. 2003; 30: 288-295.

    Dodel, R., Spottke, A., Schade-Brittinger C, Prinz H, Wenning, G., Poewe, W., Oertel WH, and for the European MSA-Study Group, K. P. S.. Doppel-blinde, randomisierte, zweiarmige Studie zur Evaluierung der Wirksamkeit und Verträglichkeit von Minocyclin bei der Behandlung von Patienten mit Multi-System-Atrophie. Hamburger Neurologenkongress 2003. Abstract

    Goerg, C., Cülle J, Goerg, K., Prinz H, and Zugmaier G. Spontaneous rupture of the spleen: ultrasound patterns, diagnosis and follow-up. Br J Radiol 76(910)[Oct], 704-711. 2003.

    Haake M, Buch M, Schoellner, C., Goebel, F., Vogel M, Hausdorf, J., Zamzow, K., Schade-Brittinger C, Maier-Boerries O, Riemert, C., and Müller H-H. Extrakorporale Stosswellentherapie (ESWT) zur Therapie der Plantarfasciitis - Prospektive randomisierte placebokontrollierte Multicenterstudie. 67.Jahrestagung der Deutschen Gesellschaft für Unfallchirurgie, 89.Tagung der Deutschen Gesellschaft für Orthopädie und chirurgische Orthopädie . 2003. Meeting Abstract (DGOOC) 2003

    Haake M, Müller H-H, Schade-Brittinger C, Prinz H, Basler, H., Streitberger, K., Schäfer H, and Molsberger, A.. The German multicenter randomized, partially blinded, prospective trial of acupuncture chronic low-back pain: a preliminary report on the rationale and design of the trial. J Altern Complement Med 9(5)[Oct], 763-770. 2003.

    Haake M, Buch M, Schoellner, C., Goebel, F., Vogel M, Mueller, I., Hausdorf, J., Zamzow, K., Schade-Brittinger C, and Müller H-H. Extracorporeal shock wave therapy for plantar fasciitis: randomised, controlled multicentre trial. BMJ 327(7406)[Jul 12], 75. 2003.

    Haake M, Schade-Brittinger C, Müller H-H, Prinz H, Basler, H., Donner-Banzhoff, N., Schäfer H, and Molsberger, A.. Acupuncture in chronic back pain. Background, development and design of the German Acupuncture trial (gerac-clbp). Z Orthop Ihre Grenzgeb 141(1)[Jan-Feb], 6-10. 2003.

    Speer R, Kuchinke W, Meisner C, Schwabedissen M, Troost R, and Wittenberg M. Systemvalidierung in klinischen Studien - Erstellung eines Validierungspakets für die KKS und andere Verbände. 2003. Informatik, Biometrie und Epidemiologie in Medizin und Biologie 34(3):368.

    2002

    Leppek R, Alfke H, Heverhagen J, Geisz E, Wittenberg M, and Klose KJ. Durchblutungsquantifizierung mittels parametrisierter dynamischer Kernspintomographie des Unterschenkels – ein VICORA-Teilprojekt. Deutsche Röntgenkongress . 2002. Abstract

    2001

    Schade-Brittinger C, Prinz H. "Modellprojekt Akupunktur" als Beispiel für die Kooperation mehrerer KKS. im Rahmen einer klinischen Studie. 2001. Informatik, Biometrie und Epidemiologie in Medizin und Biologie 32, 265-266.

    Selbmann H`K, Albrecht J, Brosteanu O, Prager R, Schade-Brittinger C, Schmoor C, Troost R, Unnebrink K. Aktivitäten der Fachgruppe Qualitätssicherung der Arbeitsgemeinschaft der Koordinierungszentren für Klinische Studien. 2001. Informatik, Biometrie und Epidemiologie in Medizin und Biologie 32, 291.

    Ohmann C, Kuchinke W, Schade-Brittinger C, Wittenberg M, Heller B, Troost R, Pommerening K, Schwabedissen M, Schlichthaar R, Roßner R, and Gerneth F. Fachgruppe "Datenmanagement/Telematik". 2001. Informatik, Biometrie und Epidemiologie in Medizin und Biologie 32, 241.

    Haake M, Sattler A, Gross MW, Schmitt J, Hildebrandt R, Müller HH. Vergleich der extrakorporalen Stoߟwellentherapie (ESWT) mit der Röntgenreizbestrahlung beim Supraspinatussehnensyndrom - Ein prospektiver randomisierter einfachblinder Parallelgruppenvergleich. 2001. Zeitschrift für Orthopädie 2001; 139:397-402.

    1999

    Frank M., Klose KJ, Wied M., Ishaque N, Schade-Brittinger C, and Arnold R. Combination therapy with octreotide and alpha-Interferon: Effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. 1999. American Journal of Gastroenterology 1999;94(5):1381-7.